Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.
Among individuals with localized (Stage I-II) melanoma, stratifying patients by a number of phenotypic variables (e.g., depth of invasion, ulceration) yields a wide range of 10-year melanoma-specific survival rates. With the possible exception of Ki-67, no molecular assessment is routinely used. However, there have been a tremendous number of studies assessing protein expression by immunohistochemistry toward the goal of better prediction of recurrence. In a previous systematic review, which required publication of multivariable prognostic models as a strict inclusion criterion, we identified 37 manuscripts that collectively reported on 62 proteins. Data for 324 proteins extracted from 418 manuscripts did not meet our inclusion criteria for that study, but are revisited here, emphasizing trends of protein expression across either melanocytic lesion progression or gradations of tumor thickness. These identified 101 additional proteins that stratify melanoma, organized according to the Hanahan and Weinberg functional capabilities of cancer.
Gould Rothberg
Bonnie E
BE
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Rimm
David L
DL
D014408:Biomarkers, Tumor; D006801:Humans; D008545:Melanoma / Q000473:pathology* / Q000503:physiopathology*; D009361:Neoplasm Invasiveness; D011237:Predictive Value of Tests; D011379:Prognosis; D012878:Skin Neoplasms / Q000473:pathology* / Q000503:physiopathology*
D014408:Biomarkers, Tumor